“Japan Society for the promotion of anti-hepatitis" was established in December 2012 for the health promotion of Japanese nation through raising awareness and response rate of examination for viral hepatitis.
In Japan, about 40,000 people died in liver disease and in this 40,000 about 35,000 are by liver cancer. This is the 4th biggest number of death in malignant tumors.
At present, it is estimated 3 to 3.7 million people living with chronic viral hepatitis B or C in our country.
Although it is possible to prevent from the progress to serious symptoms, such as liver cirrhosis or liver cancer, by finding in early stage and being treated appropriately, liver is often called silent organ, hardly recognized its disease by symptom, many receive diagnosis after advancing in severity, and having hard time in treatment.
In background, there are problem in low accomplishment of early treatment because of lack of nation’s awareness and low response rate of examination of viral hepatitis.
Ministry of Health, Labour and Welfare shows a policy to work on promotion of the prevention of the hepatitis and the early detection (Improvement of the rate of undergoing examinations) with Basic Act on Hepatitis Measures enforced in 2009.
We are aiming health promotion and support hepatitis patients by spreading accurate understanding of chronic viral hepatitis and guiding people to examination, and hoping to lead to the result of prevention from spreads, early detection and early treatment of hepatitis.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close